2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Geoffrey Y. Ku, MD, medical oncologist, discusses the efficacy of zanidatamab plus standard chemotherapy in patients with HER2-positive gastroesophageal adenocarcinoma in the ongoing phase 2 ZW25-201 trial.
Geoffrey Y. Ku, MD, medical oncologist, head, Esophagogastric Section, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the efficacy of zanidatamab (ZW25) plus standard chemotherapy in patients with HER2-positive gastroesophageal adenocarcinoma (GEA) in the ongoing phase 2 ZW25-201 trial (NCT03929666).
Overall, zanidatamab in combination with various chemotherapies has been shown to elicit high response rates of 75%, as well as a favorable disease control rate of 89%, in patients with HER2-positive GEA, Ku says. These results favorably compare with the historical data expected with trastuzumab (Herceptin) and chemotherapy alone, Ku explains
Moreover, in addition to high response rates, the duration of response was encouraging as well at a median of 16.4 months, Ku continues. However, it is believed that responses can deepen over time because and there have several patients have gone on to achieve a complete response, Ku concludes.